Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis

BACKGROUND: Postoperative docetaxel plus S-1 (DS) chemotherapy is expected to be the standard therapeutic strategy for pStage III gastric cancer based on the results of the JACCRO GC-07 study. Neoadjuvant chemotherapy (NAC) is thought to have several advantages over adjuvant settings. OBJECTIVE: Thi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Surg Oncol
Asıl Yazarlar: Kano, Masayuki, Hayano, Koichi, Hayashi, Hideki, Hanari, Naoyuki, Gunji, Hisashi, Toyozumi, Takeshi, Murakami, Kentaro, Uesato, Masaya, Ota, Satoshi, Matsubara, Hisahiro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer International Publishing 2019
Konular:
Gastrointestinal Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510880/
https://ncbi.nlm.nih.gov/pubmed/30977014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-07299-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller